

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2018

DESPATCHED ON 11TH SEPTEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A29, A31; B44, -; Cw2, -; DR7, DR12; DQ2, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	8	8	6	7	32	32	31	32	28	28	27	27				
Positive	1	0	1	2	1	0	1	8	4	6	21	15				
Negative	7	8	5	5	31	32	30	24	24	22	6	12				
NT	1	1	3	2	2	2	3	2	7	7	8	8				
% Positive	12.5%	0.0%	16.7%	28.6%	3.1%	0.0%	3.2%	25.0%	14.3%	21.4%	77.8%	55.6%				
% Negative	87.5%	100.0%	83.3%	71.4%	96.9%	100.0%	96.8%	75.0%	85.7%	78.6%	22.2%	44.4%				
				<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Positive</b>	<b>Not Assessed</b>	
				B7 B27 Multi	B7	DR52	A10	B7 B27 Multi	B7	DR52	A10	B7 B27 Multi	B7	DR52	A10	
HLA Antibody Specificity (Defined By CDC)				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES	Negative	Negative	NT	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	High background in PBL
11	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
12	YES	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	NT	NT	NT	NT	Low B-cell viability
20	YES		YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
23		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
24		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
25		YES	YES					Negative	Negative	Negative	Positive	Positive	Positive	Positive	Positive	
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
38	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
39		YES	YES					Negative	Negative	Negative	Positive	NT	NT	NT	NT	Low B-cell viability
41		YES	YES					Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	
42	YES		YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
45		YES	YES					Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
51		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Very poor cell preparation
54		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
58		YES	YES					Positive	Negative	Negative	Positive	Positive	Positive	Positive	Positive	
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
116		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
117	YES			Positive	Negative	Positive	NT	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Not enough cells
136		YES						Negative	Negative	Negative	Positive	Negative	Negative	Positive	NT	Low B-cell viability
145		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	NT	
149	YES			Negative	Negative	NT	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	NT	
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
181		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
186		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
204		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Serum 3 B-cell = Weak positive IgM or Negative (?) = Negative
223		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
227		YES	YES					Negative	Negative	NT	Negative	Negative	Negative	NT	Negative	Technical failure
268		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
351		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	No results returned
406				NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	No results returned
411		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2018

DESPATCHED ON 11TH SEPTEMBER 2018

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	0	NT	2	0	0	0	2	0	0	2	2	80	80	60
11	-	-	-	-	-	-	-	-	NT	NT	NT	NT	90	95	
12	15%	-	-	30%	15%	-	-	30%	NT	NT	NT	NT	95	95	60
20	1	1	1	1					1	1	1	1	90		90
23					1	1	1	1	1	1	4	4		90	80
24					10	10	10	10	20	20	30	30		90	80
25					1	1	1	4	4	4	8	4		99	99
28					1	1	1	1	1	6	8	1		95	80
34					1	1	1	1	4	4	6	4		95	85
38	1	1	1	1	1	1	1	1	6	6	8	8	90	98	85
39					-	-	-	2	NT	NT	NT	NT		100	100
41					-	-	40	40	-	-	40	30		95	98
42	<10%	<10%	<10%	<10%					<10%	<10%	80-100%	<10%	95		95
45					-	-	-	-	-	-	-	-		99	85
51					0	0	0	0	0	0	8	2		90	80
54					5%	5%	5%	10%	20%	40%	70%	60%		95	95
58					15	5	5	20	25	30	99	80		95	85
101					1	1	1	1	1	1	4	4			
114					1	1	1	1	2	2	8	1			
116					1	1	1	1	NT	NT	NT	NT		95	50
117	4	1	4	NT									90		
136					1	1	1	6						98	95
145					-	-	-	-	-	-	8	NT		100	100
149	-	-	NT	-									84		
162					-	-	-	-	-	-	6	-			
181					1	1	1	1	1	1	8	1		90	90
186					0	0	0	0	0	0	6	2		99	99
204					1	1	1	1	2	4	8	6		90	80
206					0	0	0	0	0	0	2	0		90	80
223					1	1	1	1	NT	NT	NT	NT		100	50
227					-	-	NT	-	-	-	NT	-		98	98
268					1	1	1	1	1	1	1	1		95	85
284					1	1	1	2	1	1	8	4		99	97
311					1	1	1	1	1	1	4	1		90	90
315					1	1	1	1	1	1	4	1		80	80
351															
406															
411					1	1	1	1	1	1	1	1		80	70

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2018

DESPATCHED ON 11TH SEPTEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A29, A31; B44, -; Cw2, -; DR7, DR12; DQ2, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	7	7	5	7	29	29	28	29	27	27	26	27				
Positive	0	0	0	0	0	0	1	1	0	0	19	2				
Negative	7	7	5	7	29	29	27	28	27	27	7	25				
NT	1	1	3	1	2	2	3	2	6	6	7	6				
% Positive	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.6%	3.4%	0.0%	0.0%	73.1%	7.4%				
% Negative	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	96.4%	96.6%	100.0%	100.0%	26.9%	92.6%				
Consensus	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>				
HLA Antibody Specificity (Defined By CDC)	B7 B27 Multi	B7	DR52	A10	B7 B27 Multi	B7	DR52	A10	B7 B27 Multi	B7	DR52	A10				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Negative	Negative	NT	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	High background in PBL
11	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
15		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
20	YES		YES	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	
24		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
38	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
39		YES	YES					Negative	Negative	Positive	Positive	NT	NT	NT	NT	Low B-cell viability
41		YES	YES					Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative	
42	YES		YES	Negative	Negative	Negative	Negative			Positive	Positive	Negative	Negative	Positive	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
51		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Very poor cell preparation
54		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
58		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
116		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
149	YES		YES	Negative	Negative	NT	Negative									
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
181		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
186		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
204		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
227		YES	YES					Negative	Negative	NT	Negative	Negative	Negative	NT	Negative	Technical failure
268		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
351		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	No results returned
406				NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	No results returned
411		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2018

DESPATCHED ON 11TH SEPTEMBER 2018

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	0	NT	0	0	0	0	0	0	0	2	0	80	80	60
11	-	-	-	-	-	-	-	-	NT	NT	NT	NT	90	95	
12	15%	-	-	-	15%	-	-	-	NT	NT	NT	NT	95	95	60
15					-	-	-	-	-	-	4	-	100	90	80
20	1	1	1	1					1	1	1	1	90		90
24					20	20	20	20	20	20	20	20		90	80
25					1	1	1	1	1	1	1	1		99	99
28					1	1	1	1	1	1	8	1		95	80
34					1	1	1	1	1	1	8	1		95	85
38	1	1	1	1	1	1	1	1	1	1	8	1		98	80
39					-	-	-	-	NT	NT	NT	NT		100	100
41					-	-	40	40	-	-	40	-		95	98
42	<10%	<10%	<10%	<10%					<10%	<10%	40-60%	<10%	95		95
45					-	-	-	-	-	-	-	-		99	85
51					0	0	0	0	0	0	6	0		90	80
54					5%	5%	5%	5%	5%	5%	70%	5%		95	95
58					5	5	5	5	20	20	99	20		95	85
101					1	1	1	1	1	1	6	4			
114					1	1	1	1	1	1	6	1			
116					1	1	1	1	NT	NT	NT	NT		95	50
149	-	-	NT	-									84		
162					-	-	-	-	-	-	6	-			
181					1	1	1	1	1	1	8	1		90	90
186					0	0	0	0	0	0	6	2		99	99
204					1	1	1	1	2	4	8	2		90	80
206					0	0	0	0	0	0	2	0		90	80
227					-	-	NT	-	-	-	NT	-		98	98
268					1	1	1	1	1	1	1	1		95	85
284					1	1	1	1	1	1	8	1		99	97
311					1	1	1	1	1	1	4	1		90	90
315					1	1	1	1	1	1	4	1		80	80
351															
406															
411					1	1	1	1	1	1	1	1		80	70